https://m2.mtmt.hu/ hun 2026-09-21 16:49 JournalArticle 31884963 VALIDATED true 0 false 2026-08-10T20:25:18.473+0000 2023-12-04T10:45:28.451+0000 2021-02-22T09:33:34.052+0000 true 10070835 xSzepesy xJudit /api/admin/10070835 Admin xSzepesy xJudit (xSE_AOK_Farmakol_Admin5_SzJ, admin) true 2025-12-22T13:45:14.704+0000 2025-12-22T13:45:14.704+0000 2023-12-04T10:45:28.747+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Kucsera, Dániel true true /api/journal/10014369 REVIEWED FRONTIERS IN PHYSIOLOGY 1664-042X true false 10014369 false 10014369 true 1664-042X Journal FOREIGN 12 609465 609465 12 2021 Funding 2009016 /api/funding/2009016 (739593 (European Union’s Horizon 2020 Research and Innovation Programme)) false true Funding 2009017 /api/funding/2009017 Nemzeti szívprogram(NVKP_16-1–2016-0017) Támogató: NKFIH false true Funding 2009018 /api/funding/2009018 (Therapeutic Development Thematic Programme of the Semmelweis University) false true Funding 2009019 /api/funding/2009019 (Research Excellence Programme of the National Research) false true Funding 2009020 /api/funding/2009020 (ÚNKP-20-4-II-20) false true Funding 2009021 /api/funding/2009021 (János Bolyai Research Scholarship) false true Funding 2009022 /api/funding/2009022 (OTKA-FK-134751) false true true 2021 true true true false true false GOLD 2026-08-10 true https://doi.org/10.3389/fphys.2021.609465 20 0 19 17 3 19 20 19 19 19 19 17 17 18 2 0 20 18 19 17 0 3 3 Folyóiratcikk Journal Article 24 19 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 6 6 6 6 2023 0 2 1 2 1 2024 0 4 3 4 3 2025 0 4 4 4 4 2026 0 4 4 4 4 Q1 false 10040905,10069244 false false false 2021-02-21T14:03:55.822+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 8 28 2 8 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 95560999 /api/authorship/95560999 Kucsera, Dániel [Kucsera, Dániel (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 1 0.125 true false false Author 10069243 /api/author/10069243 Kucsera Dániel (Farmakológia) Kucsera Dániel true true Kucsera Dániel true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561000 /api/authorship/95561000 Tóth, Viktória E. [Tóth, Viktória (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 2 0.125 false false false Author 10040905 /api/author/10040905 Tóth Viktória (Farmakológia) Tóth Viktória true 10040905 true Tóth Viktória E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561001 /api/authorship/95561001 Gergő, Dorottya [Gergő, Dorottya (Farmakológia, Far...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 3 0.125 false false false Author 10069244 /api/author/10069244 Gergő Dorottya (Farmakológia, Farmakognózia) Gergő Dorottya true true Gergő Dorottya true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561002 /api/authorship/95561002 Vörös, Imre [Vörös, Imre (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 4 0.125 false false false Author 10065328 /api/author/10065328 Vörös Imre (Farmakológia) Vörös Imre true 10065328 true Vörös Imre true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561003 /api/authorship/95561003 Onódi, Zsófia [Onódi, Zsófia (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 5 0.125 false false false Author 10061054 /api/author/10061054 Onódi Zsófia (Farmakológia) Onódi Zsófia true 10061054 true Onódi Zsófia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561004 /api/authorship/95561004 Görbe, Anikó [Görbe, Anikó (orvostudomany), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 6 0.125 false false false Author 10027602 /api/author/10027602 Görbe Anikó (orvostudomany) Görbe Anikó true 10027602 true Görbe Anikó true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561005 /api/authorship/95561005 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 7 0.125 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95561006 /api/authorship/95561006 Varga, Zoltán V. ✉ [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 8 0.125 false true true Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18462829 /api/publicationidentifier/18462829 DOI: 10.3389/fphys.2021.609465 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3389/fphys.2021.609465 https://doi.org/10.3389/fphys.2021.609465 false true PublicationIdentifier 18711558 /api/publicationidentifier/18711558 WoS: 000626031400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000626031400001 https://www.webofscience.com/wos/woscc/full-record/000626031400001 false true PublicationIdentifier 18565828 /api/publicationidentifier/18565828 Scopus: 85102321282 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85102321282 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85102321282 true true PublicationIdentifier 18565842 /api/publicationidentifier/18565842 PubMed: 33692700 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33692700 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33692700&dopt=Abstract true true SjrRating 11233325 /api/sjrrating/11233325 sjr:Q1 (2021) Scopus - Physiology (medical) FRONTIERS IN PHYSIOLOGY 1664-042X 26 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2737 /api/classificationexternal/2737 Scopus - Physiology (medical) true 2737 true Q1 DIRECT true true Reference 18503433 /api/reference/18503433 1. Adorni 2017: Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages., Atherosclerosis, 256, p. 1, DOI: 10.1016/j.atherosclerosis.2016.11.019 1 10.1016/j.atherosclerosis.2016.11.019 false true Reference 18503434 /api/reference/18503434 2. Ajam 2017: It’s time to focus on decreasing cardiovascular mortality in NAFLD population: potential use of statins and PCSK9 inhibitors., Curr. Trends Cardiol., 1, DOI: 10.35841/cardiology.1.2.55-59 2 10.35841/cardiology.1.2.55-59 false true Reference 18503435 /api/reference/18503435 3. Ballestri 2017: NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk., Adv. Ther., 34, p. 1291, DOI: 10.1007/s12325-017-0556-1 3 10.1007/s12325-017-0556-1 false true Reference 18503436 /api/reference/18503436 4. Bambha 2012: Ethnicity and non-alcoholic fatty liver disease., Hepatology, 55, p. 769, DOI: 10.1002/hep.24726 4 10.1002/hep.24726 false true Reference 18503437 /api/reference/18503437 5. Beagley 2003: Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone., FEMS Immunol. Med. Microbiol, 38, p. 13, DOI: 10.1016/s0928-8244(03)00202-5 5 10.1016/s0928-8244(03)00202-5 false true Reference 18503438 /api/reference/18503438 6. Brown 1997: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor., Cell, 89, p. 331, DOI: 10.1016/s0092-8674(00)80213-5 6 10.1016/s0092-8674(00)80213-5 false true Reference 18503439 /api/reference/18503439 7. Chen 2020: Sex-specific effects of the Nlrp3 inflammasome on atherogenesis in LDL receptor-deficient mice., JACC Basic Transl. Sci., 5, p. 582, DOI: 10.1016/j.jacbts.2020.03.016 7 10.1016/j.jacbts.2020.03.016 false true Reference 18503440 /api/reference/18503440 8. Della Torre 2020: Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling., Front. Endocrinol. (Lausanne), 11, DOI: 10.3389/fendo.2020.572490 8 10.3389/fendo.2020.572490 false true Reference 18503441 /api/reference/18503441 9. Della Torre 2014: Energy metabolism and fertility: a balance preserved for female health., Nat. Rev. Endocrinol., 10, p. 13, DOI: 10.1038/nrendo.2013.203 9 10.1038/nrendo.2013.203 false true Reference 18503442 /api/reference/18503442 10. Demers 2015: PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver., Arterios. Thromb Vasc. Biol., 35, p. 2517, DOI: 10.1161/atvbaha.115.306032 10 10.1161/atvbaha.115.306032 false true Reference 18503443 /api/reference/18503443 11. Diaz Brinton 2012: Minireview: translational animal models of human menopause: challenges and emerging opportunities., Endocrinology, 153, p. 3571, DOI: 10.1210/en.2012-1340 11 10.1210/en.2012-1340 false true Reference 18503444 /api/reference/18503444 12. Dimakopoulou 2018: PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia., Hell J. Atheroscler., 9, p. 1 12 false true Reference 18503445 /api/reference/18503445 13. Ding 2020: NLRP3 inflammasome via IL-1β regulates PCSK9 secretion., Theranostics, 10, p. 7100, DOI: 10.7150/thno.45939 13 10.7150/thno.45939 false true Reference 18503446 /api/reference/18503446 14. DiStefano 2020: NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment., Endocrinology, 161, DOI: 10.1210/endocr/bqaa134 14 10.1210/endocr/bqaa134 false true Reference 18503447 /api/reference/18503447 15. Dullaart 2017: PCSK9 inhibition to reduce cardiovascular events., N. Engl. J. Med., 376, p. 1790, DOI: 10.1056/NEJMe1703138 15 10.1056/NEJMe1703138 false true Reference 18503448 /api/reference/18503448 16. Fairweather 2014: Sex differences in inflammation during atherosclerosis., Clin. Med. Insights Cardiol., 8, p. 49, DOI: 10.4137/cmc.S17068 16 10.4137/cmc.S17068 false true Reference 18503449 /api/reference/18503449 17. Feingold 2008: Inflammation stimulates the expression of PCSK9., Biochem. Biophys. Res. Commun., 374, p. 341, DOI: 10.1016/j.bbrc.2008.07.023 17 10.1016/j.bbrc.2008.07.023 false true Reference 18503450 /api/reference/18503450 18. Ferri 2020: Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study., Atherosclerosis, 309, p. 39, DOI: 10.1016/j.atherosclerosis.2020.07.014 18 10.1016/j.atherosclerosis.2020.07.014 false true Reference 18503451 /api/reference/18503451 19. Friedman 2018: A randomized, placebo-controlled trial of cenicriviroc for treatment of non-alcoholic steatohepatitis with fibrosis., Hepatology, 67, p. 1754, DOI: 10.1002/hep.29477 19 10.1002/hep.29477 false true Reference 18503452 /api/reference/18503452 20. Gutierrez-Grobe 2010: Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens., Ann. Hepatol., 9, p. 402, DOI: 10.1016/S1665-2681(19)31616-3 20 10.1016/S1665-2681(19)31616-3 false true Reference 18503453 /api/reference/18503453 21. Hooper 2015: Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein., Circ. Res., 116, p. 193, DOI: 10.1161/circresaha.116.304637 21 10.1161/circresaha.116.304637 false true Reference 18503454 /api/reference/18503454 22. Horton 2007: Molecular biology of PCSK9: its role in LDL metabolism., Trends Biochem. Sci., 32, p. 71, DOI: 10.1016/j.tibs.2006.12.008 22 10.1016/j.tibs.2006.12.008 false true Reference 18503455 /api/reference/18503455 23. Ioannou 2016: The Role of cholesterol in the pathogenesis of NASH., Trends Endocrinol. Metab., 27, p. 84, DOI: 10.1016/j.tem.2015.11.008 23 10.1016/j.tem.2015.11.008 false true Reference 18503456 /api/reference/18503456 24. Kamari 2011: Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice., J. Hepatol., 55, p. 1086, DOI: 10.1016/j.jhep.2011.01.048 24 10.1016/j.jhep.2011.01.048 false true Reference 18503457 /api/reference/18503457 25. Koonen 2007: Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity., Diabetes, 56, p. 2863, DOI: 10.2337/db07-0907 25 10.2337/db07-0907 false true Reference 18503458 /api/reference/18503458 26. Lai 2017: E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver., JCI Insight, 2, DOI: 10.1172/jci.insight.89729 26 10.1172/jci.insight.89729 false true Reference 18503459 /api/reference/18503459 27. Lazo 2013: Prevalence of non-alcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994., Am. J. Epidemiol., 178, p. 38, DOI: 10.1093/aje/kws448 27 10.1093/aje/kws448 false true Reference 18503460 /api/reference/18503460 28. Lebeau 2019: Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice., JHEP Rep., 1, p. 418, DOI: 10.1016/j.jhepr.2019.10.009 28 10.1016/j.jhepr.2019.10.009 false true Reference 18503461 /api/reference/18503461 29. Lonardo 2019: Non-alcoholic fatty liver disease: does sex matter?, Hepatobiliary Surg. Nutr., 8, p. 164, DOI: 10.21037/hbsn.2018.12.04 29 10.21037/hbsn.2018.12.04 false true Reference 18503462 /api/reference/18503462 30. Mridha 2017: NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice., J. Hepatol., 66, p. 1037, DOI: 10.1016/j.jhep.2017.01.022 30 10.1016/j.jhep.2017.01.022 false true Reference 18503463 /api/reference/18503463 31. Musso 2013: Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis., Prog. Lipid. Res., 52, p. 175, DOI: 10.1016/j.plipres.2012.11.002 31 10.1016/j.plipres.2012.11.002 false true Reference 18503464 /api/reference/18503464 32. Paik 2019: Mortality related to nonalcoholic fatty liver disease is increasing in the United States., Hepatol. Commun., 3, p. 1459, DOI: 10.1002/hep4.1419 32 10.1002/hep4.1419 false true Reference 18503465 /api/reference/18503465 33. Panta 2015: Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials., J. Clin. Lipidol., 9, p. 217, DOI: 10.1016/j.jacl.2014.12.006 33 10.1016/j.jacl.2014.12.006 false true Reference 18503466 /api/reference/18503466 34. Peterson 2008: PCSK9 function and physiology., J. Lipid. Res., 49, p. 1152, DOI: 10.1194/jlr.E800008-JLR200 34 10.1194/jlr.E800008-JLR200 false true Reference 18503467 /api/reference/18503467 35. Ray 2017: Inclisiran in patients at high cardiovascular risk with Elevated LDL cholesterol., N. Engl. J. Med., 376, p. 1430, DOI: 10.1056/NEJMoa1615758 35 10.1056/NEJMoa1615758 false true Reference 18503468 /api/reference/18503468 36. Ridker 2017: Antiinflammatory therapy with canakinumab for atherosclerotic disease., N. Engl. J. Med., 377, p. 1119, DOI: 10.1056/NEJMoa1707914 36 10.1056/NEJMoa1707914 false true Reference 18503469 /api/reference/18503469 37. Roubtsova 2015: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice., J. Lipid. Res., 56, p. 2133, DOI: 10.1194/jlr.M061952 37 10.1194/jlr.M061952 false true Reference 18503470 /api/reference/18503470 38. Sabatine 2017: Evolocumab and clinical outcomes in patients with cardiovascular disease., N. Engl. J. Med., 376, p. 1713, DOI: 10.1056/NEJMoa1615664 38 10.1056/NEJMoa1615664 false true Reference 18503471 /api/reference/18503471 39. Sacks 2018: Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke., Int J. Stroke, 13, p. 612, DOI: 10.1177/1747493018778713 39 10.1177/1747493018778713 false true Reference 18503472 /api/reference/18503472 40. Tang 2020: Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes., Cardiovasc. Diabetol., 19, DOI: 10.1186/s12933-020-01009-4 40 10.1186/s12933-020-01009-4 false true Reference 18503473 /api/reference/18503473 41. Tang 2017: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway., Atherosclerosis, 262, p. 113, DOI: 10.1016/j.atherosclerosis.2017.04.023 41 10.1016/j.atherosclerosis.2017.04.023 false true Reference 18503474 /api/reference/18503474 42. Thomas 2017: NAFLD: a critical role for the NLRP3 inflammasome in NASH., Nat. Rev. Gastroenterol. Hepatol., 14, DOI: 10.1038/nrgastro.2017.21 42 10.1038/nrgastro.2017.21 false true Reference 18503475 /api/reference/18503475 43. Tilg 2020: A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?, Expert Opin. Investig. Drugs, 29, p. 103, DOI: 10.1080/13543784.2020.1681397 43 10.1080/13543784.2020.1681397 false true Reference 18503476 /api/reference/18503476 44. Tilg 2016: Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis., Hepatology, 64, p. 955, DOI: 10.1002/hep.28456 44 10.1002/hep.28456 false true Reference 18503477 /api/reference/18503477 45. Ventura-Clapier 2017: Sex in basic research: concepts in the cardiovascular field., Cardiovasc. Res., 113, p. 711, DOI: 10.1093/cvr/cvx066 45 10.1093/cvr/cvx066 false true Reference 18503478 /api/reference/18503478 46. Wang 2011: Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones., J. Clin. Endocrinol. Metab., 96, p. 885, DOI: 10.1210/jc.2010-2061 46 10.1210/jc.2010-2061 false true Reference 18503479 /api/reference/18503479 47. Zhang 2019: Sex differences associated with circulating pcsk9 in patients presenting with acute myocardial infarction., Sci. Rep., 9, DOI: 10.1038/s41598-018-35773-x 47 10.1038/s41598-018-35773-x false true /api/publication/31884963 Kucsera Dániel et al. Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. (2021) FRONTIERS IN PHYSIOLOGY 1664-042X 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10069243"><a href="/gui2/?type=authors&mode=browse&sel=10069243" target="_blank">Kucsera Dániel (<span class="authorship-author-name">Kucsera Dániel</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10040905"><a href="/gui2/?type=authors&mode=browse&sel=10040905" target="_blank">Tóth Viktória E. (<span class="authorship-author-name">Tóth Viktória</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10069244"><a href="/gui2/?type=authors&mode=browse&sel=10069244" target="_blank">Gergő Dorottya (<span class="authorship-author-name">Gergő Dorottya</span> <span class="authorAux-mtmt"> Farmakológia, Farmakognózia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10065328"><a href="/gui2/?type=authors&mode=browse&sel=10065328" target="_blank">Vörös Imre (<span class="authorship-author-name">Vörös Imre</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10061054"><a href="/gui2/?type=authors&mode=browse&sel=10061054" target="_blank">Onódi Zsófia (<span class="authorship-author-name">Onódi Zsófia</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027602"><a href="/gui2/?type=authors&mode=browse&sel=10027602" target="_blank">Görbe Anikó (<span class="authorship-author-name">Görbe Anikó</span> <span class="authorAux-mtmt"> orvostudomany</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10010125"><a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (<span class="authorship-author-name">Ferdinandy Péter</span> <span class="authorAux-mtmt"> Farmakológia, molekuláris medicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028393"><a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V. ✉ (<span class="authorship-author-name">Varga Zoltán</span> <span class="authorAux-mtmt"> kardiovaszkuláris kutatás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;31884963" target="_blank">Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice</a></div> <div> <span class="journal-title">FRONTIERS IN PHYSIOLOGY</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/1664-042X">1664-042X</a>)</span>: <span class="journal-volume">12</span> <span class="page"> Paper 609465. 12 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3389/fphys.2021.609465" target="_blank" href="https://doi.org/10.3389/fphys.2021.609465"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000626031400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000626031400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85102321282" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85102321282"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33692700" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33692700&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physiology (medical)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physiology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 20</span> | Független: 18 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 19 | Scopus jelölt:&nbsp;19 | WoS/Scopus jelölt:&nbsp;19 | DOI jelölt:&nbsp;20 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;31884963&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 3 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 31884963</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> HCEMM(739593) Támogató: Horizon 2020, National Heart Program(NVKP-16-1-2016-0017) Támogató: NKFIH, (Therapeutic Development Thematic Programme of the Semmelweis University), (Research Excellence Programme of the National Research), (ÚNKP-20-4-II-20), (János Bolyai Research Scholarship), (OTKA-FK-134751) </div> <div class="lastModified">Utolsó módosítás: 2023.12.04. 11:45 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> </div></div>